Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minn. Appellate Court Will Reconsider Access To GlaxoSmithKline Documents On Re-Importation

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline may be ordered to make public 45 documents related to Minnesota Attorney General's claim that the company attempted to boycott Canadian pharmacies.

You may also be interested in...



Manufacturers Should Perform Due Diligence On Potential Distributors, Attorney Advises

Drug companies should audit wholesalers' facilities to reduce counterfeits, Arnall Golden Gregory attorney Alan Minsk tells Healthcare Distribution Management Association.

Purdue Signs On To Market Labopharm's Once-Daily Tramadol

Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.

Merck KGaA Boosts U.S. Generic Market Presence With Genpharm Expansion

Genpharm opens office in New York headed by former Able CEO Robert Mauro.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel